Back to discover
Disease

Diffuse Intrinsic Pontine Glioma

Late-stage therapeutic developmentEmerging research
MeSHDiffuse Intrinsic Pontine Glioma
1
Publications
24
Clinical trials
2
Associated genes
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 3 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Clinical Milestones12View all 12
Results posted 3
Results expected 3
Recently completed 2
Other updates 4
+4 more in the activity timeline below
Activity timeline12

Clinical trials

14 sponsors · 0 new · 1 completed in the last 12 months (net -3)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
11
Late-stage
6
Completed
Late-stage studies

A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma

Phase 3 · Active, not recruiting · NRG Oncology

A Phase 3, Open-label, Randomized 2-arm Study Comparing the Clinical Efficacy and Safety of Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

Phase 3 · Active, not recruiting · Ivy Brain Tumor Center

Randomized Phase 2b Study of Safety And Efficacy Of TVI-Brain-1 Combined With Conformal Radiotherapy And Temozolomide Vs Standard Therapy In Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

Phase 2/3 · Active, not recruiting · TVAX Biomedical

An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)

Phase 4 · Active, not recruiting · Novartis Pharmaceuticals

A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Evaluate Safety and Efficacy pf ASC40 Tablets Combined With Bevacizumab in Subjects With Recurrent Glioblastoma

Phase 3 · Active, not recruiting · Ascletis Pharmaceuticals Co., Ltd.

A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma

Phase 2/3 · Completed · National Cancer Institute (NCI)
Recently completed

Tofacitinib: Suppressing Tumor Invasion in Recurrent GBM Patients

Phase 3 · Completed · University of Texas Southwestern Medical Center

Safety and Efficacy Study of Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

Phase 2 · Completed · Washington University School of Medicine

A Phase II Open-label Study Investigating the Efficacy, Safety and Pharmacokinetic Properties of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma

Phase 2 · Completed · Oblato, Inc.

A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma

Phase 2/3 · Completed · National Cancer Institute (NCI)

A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination With Ipilimumab Across Different Lines of Glioblastoma

Phase 3 · Completed · Bristol-Myers Squibb

Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma

Phase 3 · Completed · Novartis Pharmaceuticals

Research activity

1 paper

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Major themes3
  • Brain Stem Neoplasms1
  • Diffuse Intrinsic Pontine Glioma1
  • Glioma1
Leading journals1
  • Cancer cell1
Leading researchers8
  • Alonso MM1
  • Anderson AC1
  • Ausejo-Mauleon I1
  • Becher OJ1
  • Collantes M1
  • De Andrea C1
  • de Biagi-Junior CAO1
  • de la Nava D1
Affiliations (unnormalised)6
  • Center for Genetic Medicine Research1
  • Dana-Farber Boston Children's Cancer and Blood Disorders Center1
  • Division of Oncology and Children's Research Center1
  • Evergrande Center for Immunologic Diseases1
  • Health Research Institute of Navarra (IdiSNA)1
  • James L. Winkle College of Pharmacy1

Associated genes

2 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

H3C30.02OR7E240.00

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A rare, aggressive brain tumor that forms in the GLIAL CELLS in the PONS.

Identifiers
MeSHDiffuse Intrinsic Pontine Glioma
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.